Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Shima Pashaei

Citation

Annals of Oncology (2018) 29 (suppl_9): ix1-ix7. 10.1093/annonc/mdy426

Authors

S. Pashaei1, R. Dolatkhah1, Z. Sanaat2, P. Jabbaripour1, G.H. de Bock3

Author affiliations

  • 1 Tabriz University Of Medical Sciences, Hematology and Onclogy Research Center, 5166614731 - Tabriz/IR
  • 2 Internal Medicine Department Hematology & Oncology, Shahid Ghazi Medical Center,Tabriz University of Medical Sciences, 51656 - Tabriz/IR
  • 3 University Medical Center, Oncological Epidemiology, 57468936541 - Groningen/NL
More

Resources

Background

Historically, breast cancer (BC) incidence and survival in middle income countries are lower than in developed countries. The aim of this study was to provide recent data on the BC incidence and survival in Iran.

Methods

Data of the patients diagnosed with confirmed BC as registered in the East Azerbaijan cancer registry between 2011 and 2015 were linked to the regional death registration system. The 5 year age standardized incidence rates (ASIRs) for BC were estimated. With Kaplan Meier methods, the BC specific one and five year survival rates were estimated.

Results

There were 2,677 patients diagnosed with breast cancer, 97.6% (n = 2612) were female, with a mean age of 51 of years (SD: 13.28). Over the study period, the ASIRs increased from 1.08 to 16.12 per 100,000. The one and five year BC specific survival rates were 96.5%, 59.3%, respectively.

Conclusions

We observed a sharp increase in incidence BC, which might be explained by the improvement of compliance to the cancer registration. Survival rates are still low compared to western countries.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Hematology and Oncology Reserach Center.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings